AC682

DRUG2 trials

Sponsors

Accutar Biotechnology Inc

Conditions

Breast Cancer

Phase 1

A Study of AC682 for the Treatment of Locally Advanced or Metastatic ER+ Breast Cancer

TerminatedNCT05080842

Accutar Biotechnology IncBreast Cancer

Start: 2021-11-12End: 2024-04-04Updated: 2025-02-13

A Study of AC682 In Chinese Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer

TerminatedNCT05489679

Accutar Biotechnology IncBreast Cancer

Start: 2022-10-01End: 2023-09-28Updated: 2024-01-25